| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, 40136 Bologna, Italy [K. S., S. B., M. Sa., M. Se, D. M., P. P., M. C. M., N. B.]; and Istituto di Cancerologia, Università degli Studi, 40126 Bologna, Italy [P-L. L.]
The disappointingly low survival rate observed in Ewing's sarcoma (ES)/peripheral neuroectodermal tumor (PNET) despite the adoption of aggressive multimodal treatments prompted us to study the existence of autocrine circuits to be used as innovative therapeutic targets. Of the several circuits analyzed, only the insulin-like growth factor receptor (IGF-IR)-mediated loop was found to be constantly present both in cell lines and clinical samples, suggesting a role for this autocrine circuit in the pathogenesis of ES/PNET. The in vitro inhibition of the IGF-IR-mediated circuit by the specific IGF-IR binding antibody 
IR3 suppressed the growth of ES/PNET cells by decreasing the proliferative rate and increasing apoptosis. IR3 also significantly inhibited the ability of ES/PNET cells to grow in soft agar and to migrate following a chemotactic stimulus. Inactivation of the IGF-IR signaling pathway may therefore be considered as an effective therapeutic modality for patients with ES/PNET.
1 This work was supported by the Consiglio Nazionale delle Ricerche, the Progetto Finalizzato Applicazioni Cliniche della Ricerca Oncologica; by the Istituti Ortopedici Rizzoli, Ricerca Corrente; and by the Ministero della Sanità, Ricerca Finalizzata. S. B. is a recipient of a fellowship from Associazione Italiana per la Ricerca sul Cancro. M. C. M. is a recipient of a fellowship from Federazione Italiana per la Ricerca sul Cancro.
2 To whom requests for reprints should be addressed, at the Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Via di Barbiano 1/10, 40136 Bologna, Italy.
Received 6/28/96. Accepted 8/27/96.
This article has been cited by other articles:
|
|
 |
|
  U. McDermott and J. Settleman Personalized Cancer Therapy With Selective Kinase Inhibitors: An Emerging Paradigm in Medical Oncology J. Clin. Oncol., November 20, 2009; 27(33): 5650 - 5659. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. T. Kurmasheva, L. Dudkin, C. Billups, L. V. Debelenko, C. L. Morton, and P. J. Houghton The Insulin-like Growth Factor-1 Receptor-Targeting Antibody, CP-751,871, Suppresses Tumor-Derived VEGF and Synergizes with Rapamycin in Models of Childhood Sarcoma Cancer Res., October 1, 2009; 69(19): 7662 - 7671. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Ordonez, D. Osuna, D. Herrero, E. de Alava, and J. Madoz-Gurpide Advances in Ewing's Sarcoma Research: Where Are We Now and What Lies Ahead? Cancer Res., September 15, 2009; 69(18): 7140 - 7150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Zha, C. O'Brien, H. Savage, L.-Y. Huw, F. Zhong, L. Berry, G. D. Lewis Phillips, E. Luis, G. Cavet, X. Hu, et al. Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer Mol. Cancer Ther., August 1, 2009; 8(8): 2110 - 2121. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Huang, A. Greer, W. Hurlburt, X. Han, R. Hafezi, G. M. Wittenberg, K. Reeves, J. Chen, D. Robinson, A. Li, et al. The Mechanisms of Differential Sensitivity to an Insulin-like Growth Factor-1 Receptor Inhibitor (BMS-536924) and Rationale for Combining with EGFR/HER2 Inhibitors Cancer Res., January 1, 2009; 69(1): 161 - 170. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Y. Kim, J. A. Toretsky, D. Scher, and L. J. Helman The Role of IGF-1R in Pediatric Malignancies Oncologist, January 1, 2009; 14(1): 83 - 91. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Martins, J. L. Ordonez, A. Garcia-Sanchez, D. Herrero, V. Sevillano, D. Osuna, C. Mackintosh, G. Caballero, A. P. Otero, C. Poremba, et al. A Pivotal Role for Heat Shock Protein 90 in Ewing Sarcoma Resistance to Anti-Insulin-like Growth Factor 1 Receptor Treatment: In vitro and In vivo Study Cancer Res., August 1, 2008; 68(15): 6260 - 6270. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Carrillo, E. Garcia-Aragoncillo, D. Azorin, N. Agra, A. Sastre, I. Gonzalez-Mediero, P. Garcia-Miguel, A. Pestana, S. Gallego, D. Segura, et al. Cholecystokinin Down-Regulation by RNA Interference Impairs Ewing Tumor Growth Clin. Cancer Res., April 15, 2007; 13(8): 2429 - 2440. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Martins, C. Mackintosh, D. H. Martin, M. Campos, T. Hernandez, J.-L. Ordonez, and E. de Alava Insulin-Like Growth Factor I Receptor Pathway Inhibition by ADW742, Alone or in Combination with Imatinib, Doxorubicin, or Vincristine, Is a Novel Therapeutic Approach in Ewing Tumor. Clin. Cancer Res., June 1, 2006; 12(11): 3532 - 3540. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Cohen, Z. Zheng, R. Bray, Y. Zhao, L. A. Sherman, S. A. Rosenberg, and R. A. Morgan Recognition of Fresh Human Tumor by Human Peripheral Blood Lymphocytes Transduced with a Bicistronic Retroviral Vector Encoding a Murine Anti-p53 TCR J. Immunol., November 1, 2005; 175(9): 5799 - 5808. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Castillero-Trejo, S. Eliazer, L. Xiang, J. A. Richardson, and R. L. Ilaria Jr. Expression of the EWS/FLI-1 Oncogene in Murine Primary Bone-Derived Cells Results in EWS/FLI-1-Dependent, Ewing Sarcoma-Like Tumors Cancer Res., October 1, 2005; 65(19): 8698 - 8705. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Scotlandi, M. C. Manara, G. Nicoletti, P.-L. Lollini, S. Lukas, S. Benini, S. Croci, S. Perdichizzi, D. Zambelli, M. Serra, et al. Antitumor Activity of the Insulin-Like Growth Factor-I Receptor Kinase Inhibitor NVP-AEW541 in Musculoskeletal Tumors Cancer Res., May 1, 2005; 65(9): 3868 - 3876. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Kitlinska, K. Abe, L. Kuo, J. Pons, M. Yu, L. Li, J. Tilan, L. Everhart, E. W. Lee, Z. Zukowska, et al. Differential Effects of Neuropeptide Y on the Growth and Vascularization of Neural Crest-Derived Tumors Cancer Res., March 1, 2005; 65(5): 1719 - 1728. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ahlen, J. Wejde, O. Brosjo, A. von Rosen, W.-H. Weng, L. Girnita, O. Larsson, and C. Larsson Insulin-Like Growth Factor Type 1 Receptor Expression Correlates to Good Prognosis in Highly Malignant Soft Tissue Sarcoma Clin. Cancer Res., January 1, 2005; 11(1): 206 - 216. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. K. Williamson, B. C. Dibling, J. R. Boyne, P. Selby, and S. A. Burchill Basic Fibroblast Growth Factor-induced Cell Death Is Effected through Sustained Activation of p38MAPK and Up-regulation of the Death Receptor p75NTR J. Biol. Chem., November 12, 2004; 279(46): 47912 - 47928. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. V. Allander, P. B. Illei, Y. Chen, C. R. Antonescu, M. Bittner, M. Ladanyi, and P. S. Meltzer Expression Profiling of Synovial Sarcoma by cDNA Microarrays : Association of ERBB2, IGFBP2, and ELF3 with Epithelial Differentiation Am. J. Pathol., November 1, 2002; 161(5): 1587 - 1595. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Chung, R. E. Bachelder, E. A. Lipscomb, L. M. Shaw, and A. M. Mercurio Integrin ({alpha}6{beta}4) regulation of eIF-4E activity and VEGF translation: a survival mechanism for carcinoma cells J. Cell Biol., July 8, 2002; 158(1): 165 - 174. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Benini, M. C. Manara, N. Baldini, V. Cerisano, Massimo Serra, M. Mercuri, P.-L. Lollini, P. Nanni, P. Picci, and K. Scotlandi Inhibition of Insulin-like Growth Factor I Receptor Increases the Antitumor Activity of Doxorubicin and Vincristine against Ewing's Sarcoma Cells Clin. Cancer Res., June 1, 2001; 7(6): 1790 - 1797. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. de Alava and J. Pardo Ewing Tumor: Tumor Biology and Clinical Applications International Journal of Surgical Pathology, January 1, 2001; 9(1): 7 - 17. [Abstract] [PDF]
|
|
|
|
|
|
L. Landuzzi, C. De Giovanni, G. Nicoletti, I. Rossi, C. Ricci, A. Astolfi, L. Scopece, K. Scotlandi, M. Serra, G. P. Bagnara, et al. The Metastatic Ability of Ewing's Sarcoma Cells Is Modulated by Stem Cell Factor and by Its Receptor c-kit Am. J. Pathol., December 1, 2000; 157(6): 2123 - 2131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Scotlandi, N. Baldini, V. Cerisano, M. C. Manara, S. Benini, M. Serra, P.-L. Lollini, P. Nanni, G. Nicoletti, G. Bernard, et al. CD99 Engagement: An Effective Therapeutic Strategy for Ewing Tumors Cancer Res., September 1, 2000; 60(18): 5134 - 5142. [Abstract] [Full Text]
|
|
|
|
|
|
E. de Alava, A. Panizo, C. R. Antonescu, A. G. Huvos, F. J. Pardo-Mindan, F. G. Barr, and M. Ladanyi Association of EWS-FLI1 Type 1 Fusion with Lower Proliferative Rate in Ewing’s Sarcoma Am. J. Pathol., March 1, 2000; 156(3): 849 - 855. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Toretsky, M. Thakar, A. E. Eskenazi, and C. N. Frantz Phosphoinositide 3-Hydroxide Kinase Blockade Enhances Apoptosis in the Ewing's Sarcoma Family of Tumors Cancer Res., November 1, 1999; 59(22): 5745 - 5750. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Xie, B. Skytting, G. Nilsson, B. Brodin, and O. Larsson Expression of Insulin-like Growth Factor-1 Receptor in Synovial Sarcoma: Association with an Aggressive Phenotype Cancer Res., August 1, 1999; 59(15): 3588 - 3591. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Manes, M. Llorente, R. A. Lacalle, C. Gomez-Mouton, L. Kremer, E. Mira, and C. Martinez-A The Matrix Metalloproteinase-9 Regulates the Insulin-like Growth Factor-triggered Autocrine Response in DU-145 Carcinoma Cells J. Biol. Chem., March 12, 1999; 274(11): 6935 - 6945. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Toretsky, T. Kalebic, V. Blakesley, D. LeRoith, and L. J. Helman The Insulin-like Growth Factor-I Receptor Is Required for EWS/FLI-1 Transformation of Fibroblasts J. Biol. Chem., December 5, 1997; 272(49): 30822 - 30827. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Giampuzzi, G. Botti, M. Cilli, R. Gusmano, A. Borel, P. Sommer, and A. Di Donato Down-regulation of Lysyl Oxidase-induced Tumorigenic Transformation in NRK-49F Cells Characterized by Constitutive Activation of Ras Proto-oncogene J. Biol. Chem., July 27, 2001; 276(31): 29226 - 29232. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
